Effect of Renal Impairment on the Pharmacokinetics and Safety of Rivipansel in Subjects with Renal Impairment and in Healthy Subjects

被引：0
|
作者：
Tammara, Brinda [1 ]
Ryan, Kelly [1 ]
Plotka, Anna [1 ]
Shafer, Frank E. [1 ]
Wei, Hua [2 ]
Readett, David [3 ]
Fang, Annie [4 ]
Korth-Bradley, Joan [1 ]
机构：
[1] Pfizer Inc, Collegeville, PA USA
[2] Pfizer Inc, Shanghai, Peoples R China
[3] Pfizer Inc, Groton, CT 06340 USA
[4] Pfizer Inc, New York, NY USA
来源：
BLOOD | 2018年 / 132卷
关键词：
D O I：
10.1182/blood-2018-99-111926
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1083
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pharmacokinetics and Safety of Ebastine in Healthy Subjects and Patients with Renal Impairment
    Robert J. Noveck
    Richard A. Preston
    Suzanne K. Swan
    [J]. Clinical Pharmacokinetics, 2007, 46 : 525 - 534
  • [2] Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment
    Noveck, Robert J.
    Preston, Richard A.
    Swan, Suzanne K.
    [J]. CLINICAL PHARMACOKINETICS, 2007, 46 (06) : 525 - 534
  • [3] Fesoterodine pharmacokinetics in subjects with renal impairment vs. healthy subjects
    Malhotra, Bimal
    Wood, Nolan
    Guna, Zhonghong
    Gandelman, Kuan
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 (06) : 998 - 998
  • [4] Effect of Renal or Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intravenous Rivipansel
    Tammara, Brinda K.
    Ryan, Kelly
    Plotka, Anna
    Shafer, Frank E.
    Wei, Hua
    Readett, David
    Fang, Annie
    Korth-Bradley, Joan M.
    [J]. CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (08): : 918 - 928
  • [5] The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. CANCER RESEARCH, 2014, 74 (19)
  • [6] The Pharmacokinetics and Safety Of Idelalisib In Subjects With Severe Renal Impairment
    Jin, Feng
    Robeson, Michelle
    Zhou, Huafeng
    Hisoire, Grace
    Ramanathan, Srini
    [J]. BLOOD, 2013, 122 (21)
  • [7] Pharmacokinetics and Safety of Momelotinib in Subjects With Hepatic or Renal Impairment
    Xin, Yan
    Kawashima, Jun
    Weng, Winnie
    Kwan, Ellen
    Tarnowski, Thomas
    Silverman, Jeffrey A.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 58 (04): : 522 - 532
  • [8] The pharmacokinetics and safety of darapladib in subjects with severe renal impairment
    Magee, Mindy He
    Shaddinger, Bonnie
    Collins, David
    Siddiqi, Shabana
    Soffer, Joseph
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 80 (04) : 654 - 661
  • [9] The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
    F. Jin
    M. Robeson
    H. Zhou
    G. Hisoire
    S. Ramanathan
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 1133 - 1141
  • [10] The pharmacokinetics and safety of idelalisib in subjects with severe renal impairment
    Jin, F.
    Robeson, M.
    Zhou, H.
    Hisoire, G.
    Ramanathan, S.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (06) : 1133 - 1141
12345